ICES. 2023. Working Group on Southern Horse Mackerel, Anchovy and Sardine (WGHANSA).

The ICES Working Group on Southern horse mackerel, anchovy and sardine (WGHANSA) assessed the status of anchovy in Atlantic Iberian waters (ane.27.9a; western and southern components) and horse mackerel in Atlantic Iberian waters (hom.27.9a) in the May meeting. The status of anchovy in Bay of Biscay (ane.27.8), sardine in southern Celtic Seas and the English Channel (pil.27.7), sardine in Bay of Biscay (pil.27.8abd) and sardine in Cantabrian Sea and Atlantic Iberian waters (pil.27.8c9a) will be assessed in the November meeting. The status of jack mackerel in Subdivision 10.a.2 (Azores grounds) (jaa.10.a2) won’t be assessed this year, since the advice is provided biannually. The stock of anchovy in Bay of Biscay (ane.27.8) has been above Blim since the reopening of the fishery in 2010. SSB in 2023 has been estimated as the second highest of the historical series. Recruitment (age 1 biomass at the beginning of the year) in 2024 is estimated above the average of the time-series. Harvest rates (catch/SSB) have been stable in the last years. The stock of anchovy in Atlantic Iberian waters (ane.27.9a) is composed by the western component (distributed in areas 9.a North, Central–North, and Central–South) and the southern component (distributed in area 9.a South). The advice is provided for the two components separately for the management calendar from July to June next year. Based on the MSE work developed for each component, the advice is based for the first time on constant harvest rate rules. For the western component, the combined PELACUS and PELAGO acoustic biomass estimate is used as an indicator of stock development and the advice is based on the stock indicator for 2023, multiplied by a constant harvest rate of 0.25, with no biomass safeguard. For the southern component, the relative SSB from an analytical assessment conducted with GADGET is used as the index of stock size development and the advice is based on the stock indicator for 2023, multiplied by a constant harvest rate of 0.5 with a biomass safeguard. In the last years sardine in the Bay of Biscay (pil.27.8abd) shows a decreasing trend in SSB. In 2023 spawning-stock biomass is estimated below MSY Btrigger, Bpa and above Blim. Since 2013 the fishing mortality has been oscillating above FMSY and Fpa, and below Flim. The advice for sardine in southern Celtic Seas and the English Channel (pil.27.7) is based on the PELTIC survey biomass index in the total area. The index ratio indicates an increase of 62% in 2023 compared with the two previous years. The biomass (age 1+) of sardine in Atlantic Iberian waters (pil.27.8c9a) in 2023 is estimated to be above MSY Btrigger, Bpa and Blim for the fourth consecutive year. Fishing mortality in 2022 is below FMSY. ICES advice is based on the ICES MSY advice rule. However, the catch options explored for 2024 include several harvest control rules that were assessed by ICES as precautionary. The SSB of horse mackerel in Atlantic Iberian waters (hom.27.9a) fluctuated from 1992 (the beginning of the assessment) to 2013 and afterwards has increased continuously to historical maximum values in 2023. In 2023 SSB is estimated at 1 214 200 tonnes, well above MSY Btrigger, Bpa, and Blim. Fishing mortality has been below FMSY over the whole time-series, with a decreasing trend in the last years. Recruitment shows a decreasing trend from 2017 to 2021 but is still above the average of the time series. The lack of the survey index in 2019 and 2020 is reflected in larger confidence intervals for SSB and recruitment in the last years. The jack mackerel in Subdivision 10.a.2 (Azores grounds) (jaa.10.a2) is classified in category 5 and advice is provided biannually. The latest advice for this stock was provided last year.This work was mainly funded by a European Union-Next Generation EU project. Agreement of the Ministry of Agriculture, Fishing and Food, as well as the Spanish Research Council (CSIC) through the Spanish Oceanographic Institute (IEO). Project Math4Fish: New tools for mathemat-ical modelling in stock assessment of spanish fisheries

Portable hemoglobinometer is a reliable technology for the follow-up of venesections tolerance in hemochromatosis.

International audienceThe treatment of HFE-related hemochromatosis, one of the most common genetic diseases, is based on phlebotomies whose tolerance is evaluated by regular monitoring of hemoglobin. Using a portable hemoglobinometer (PH) could provide an easy and fast determination of hemoglobin. Therefore, the aim of the present study was to compare, in hemochromatosis patients treated by bloodletting, the hemoglobin concentrations as assayed, on capillary blood, by a PH device and, on venous blood, by a cell counter (CC) device. For a total period of 12 weeks duration, all patients undergoing phlebotomies in the same hospital outpatient unit had hemoglobin determinations both by the HemoCue and by the laboratory's DxH 800 Coulter. To evaluate the sensitivity and specificity of the HemoCue, patients were classified as presenting or not anemia as defined by hemoglobin level below 11g/dl. Measurements of hemoglobin were performed in 122 patients. The sensitivity and specificity of PH compared to CC were 100 and 98.1%, respectively. Capillary hemoglobin by PH slightly underestimated venous hemoglobin by CC. The Pearson's correlation coefficient between PH and CC was 0.80 (P<0.0001). PH is a reliable, quick and easy technology, which can be proposed to follow-up the tolerance of venesections in hemochromatosis patients

Avoiding falsely low creatinine concentrations measured in patients treated with N-acetylcysteine for acetaminophen intoxication using enzymo-amperometric method - An in vitro and in vivo study

International audienceBACKGROUND: Circulating creatinine is a biomarker of paramount importance in clinical practice. In cases of acetaminophen (APAP) intoxication, the antidote, N-acetylcysteine (NAC), interferes with commonly used creatininase-peroxidase methods. This study aimed to assess whether creatininase-amperometric methods were affected in this context. METHODS: This study includes in vitro interference tests, involving four creatinine assays using NAC-spiked plasma pools and an in vivo retrospective study comparing creatininase-peroxidase and creatininase-amperometric measurements in patients presenting with NAC-treated APAP poisoning. RESULTS: Creatininase-peroxidase method was impacted by NAC interference in a clinically-significant manner at therapeutic NAC levels (basal value recovery of 80 % and 70 % for 500 and 1000 mg.L(-1) of NAC, respectively), surpassing the desirable Reference Change Value (RCV%). Enzymo-amperometric methods were not impacted. Among patients, a mean bias of -45.2 ± 28.0 % was observed for the peroxidase detection method compared to the amperometric in those who received NAC prior plasma sampling and -2.7 ± 5.4 % in those who did not. CONCLUSIONS: Our findings indicate that enzymo-amperometric creatinine assays remain unaffected by NAC interference due to the absence of the peroxidase step in the analytical process. Therefore, these methods are suitable to prevent spurious hypocreatininemia in APAP intoxicated patients undergoing NAC therapy

Genotype-dependent response to desmopressin in hemophilia A and proposal of a predictive response score

International audienceDesmopressin (DDAVP) is used in patients with moderate/mild hemophilia A (PWMH) to increase their factor VIII (FVIII) level and, if possible, normalize it. However, its effectiveness varies between individuals. The GIDEMHA study aims to investigate the influence of F8 gene variants. The study collected the evolution of FVIII levels from therapeutic intravenous DDAVP tests in 4 French hemophilia treatment centers. A pharmacological analysis was performed associated with efficacy scores according to F8 variants: absolute and relative responses, as well as new scores: absolute duration (based on duration with FVIII ≥0.50 IU.mL-1) and relative duration (based on half-life). From enrolled 439 PWMH, 327 had a hot-spot F8 variant (with ≥5 PWMH). For these, the median (min-max) basal and peak FVIII were 0.20 (0.02-0.040) and 0.74 (0.14-2.18) IU.mL-1 respectively, with FVIII recovery being 3.80 IU.ml-1 (1.15-14.75). The median FVIII half-life was 3.9h (0.7-15.9h). FVIII was normalized (≥0.50 IU.mL-1) in 224/327 PWMH (69%) and the median time with normalized FVIII was 3.9h (0.0-54.1h). Following the response profiles to DDAVP defined by the 4 efficacy scores, 4 groups of F8 variants were isolated then compared into survival curves with normalized FVIII (p&amp;lt;0.0001): “long lastingly effective” [p.(Glu739Lys), p.(Ser2030Asn), p.(Arg2178His), p.(Gln2208Glu) and T-stretch deletion in intron 13]; “moderately effective” [p.(Ser112Phe), p.(Ala219Thr), p.(Thr2105Ile), p.Phe2146Ser) and p.(Asp2150Asn)]; “moderately ineffective” [p.Ala81Asp), p.(Gln324Pro), p.(Tyr492His), p.(Arg612Cys), p.(Met701Val), p.(Val2035Asn) and p.(Arg2178Cys)]; and “frequently ineffective” [c.-219C&amp;gt;T, p.(Cys2040Tyr), p.(Tyr2169His), p.(Pro2319Leu) and p.(Arg2326Gln)]. In view of our data, we propose indications for DDAVP-use in PWMH based on F8 variants for minor and major invasive procedures.Clinical Trial: Registration number (trial ID): NCT05628558, Trial registry: ClinicalTrials.gov (http://www.clinicaltrials.gov/), Type of Study: Multicenter stud

Early detection of plasma D-lactate: Toward a new highly-specific biomarker of bacteraemia?

International audienceBackground: Bloodstream infections are a leading cause of mortality. Their detection relies on blood cultures (BCs) but time to positivity is often between tens of hours and days. D-lactate is a metabolite widely produced by bacteria but very few in human. We aimed to evaluate D-lactate, D-lactate/L-lactate ratio and D-lactate/total lactate ratio in plasma as potential early biomarkers of bacteraemia on a strictly biological standpoint. Methods: A total of 228 plasma specimens were collected from patients who had confirmed bacteraemia (n = 131) and healthy outpatients (n = 97). Specific L-lactate and D-lactate analyses were performed using enzymatic assays and analytical performances of D-lactate, D-lactate/total lactate and D-lactate/L-lactate ratios for the diagnosis of bacteraemia were assessed. Results: A preliminary in vitro study confirmed that all strains of Escherichia coli, Klebsiella pneumoniae and Staphylococcus aureus were able to produce D-lactate at significant levels. In patients, plasma D-lactate level was the most specific biomarker predicting a bacteraemia profile with a specificity and predictive positive value of 100% using a cut-off of 131 μmol.L−1. However, sensitivity and negative predictive value were rather low, estimated at 31% and 52%, respectively. D-lactate displayed an Area Under Receiver Operating Characteristic (AUROC) curve of 0.696 with a P value &lt; 0.0001. There was no difference of D-lactate levels between BCs bottles positive for Gram-positive or Gram-negative bacteria (p = 0.55). Conclusion: D-lactate shows promise as a specific early biomarker of bacterial metabolism. The development of rapid automated assays could raise clinical applications for infectious diseases diagnosis including early bacteraemia prediction. © 2023 The Author

Earth, water, air, fire – human-environment relationships in the multi-proxy palaeoecological study at Serteya in Western Russia

International audienc

Earth, water, air, fire – human-environment relationships in the multi-proxy palaeoecological study at Serteya in Western Russia

International audienc

Was it better to build on pile? - the lake environment and the life of the Neolithic settler

International audienc